{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:18:33Z","timestamp":1769123913384,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2011\/39\/CN"],"award-info":[{"award-number":["EMA\/2011\/39\/CN"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00198-015-3441-2","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T14:08:31Z","timestamp":1450793311000},"page":"1857-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study"],"prefix":"10.1007","volume":"27","author":[{"name":"on behalf of the EU-ADR Consortium","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Coloma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M. C.","family":"Herings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pecchioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mosseveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van der Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"issue":"6 Suppl A","key":"3441_CR1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.18553\/jmcp.2006.12.S6-A.S10","volume":"12","author":"MB O\u2019Connell","year":"2006","unstructured":"O\u2019Connell MB (2006) Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. J Manag Care Pharma: JMCP 12(6 Suppl A):S10\u2013S19, quiz S26-18","journal-title":"J Manag Care Pharma: JMCP"},{"issue":"Suppl 2","key":"3441_CR2","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"RG Russell","year":"2007","unstructured":"Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150\u2013S162. doi: 10.1542\/peds.2006-2023H","journal-title":"Pediatrics"},{"issue":"9","key":"3441_CR3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. doi: 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"3441_CR4","unstructured":"European Medicines Agency 2011 EudraVigilance-Human Annual Report. Accessible at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2013\/06\/WC500144560.pdf (2013)"},{"issue":"21","key":"3441_CR5","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","volume":"56","author":"S Elmariah","year":"2010","unstructured":"Elmariah S, Delaney JA, O\u2019Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, Halperin JL (2010) Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 56(21):1752\u20131759. doi: 10.1016\/j.jacc.2010.05.050","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3441_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/hrt.2010.205096","volume":"97","author":"JL d\u2019Arcy","year":"2011","unstructured":"d\u2019Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B (2011) Valvular heart disease: the next cardiac epidemic. Heart 97(2):91\u201393. doi: 10.1136\/hrt.2010.205096","journal-title":"Heart"},{"issue":"7","key":"3441_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM196602172740701","volume":"274","author":"JR Graham","year":"1966","unstructured":"Graham JR, Suby HI, LeCompte PR, Sadowsky NL (1966) Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 274(7):359\u2013368. doi: 10.1056\/NEJM196602172740701","journal-title":"N Engl J Med"},{"issue":"1","key":"3441_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000441-196707000-00001","volume":"254","author":"JR Graham","year":"1967","unstructured":"Graham JR (1967) Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 254(1):1\u201312","journal-title":"Am J Med Sci"},{"issue":"5915","key":"3441_CR9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.2.5915.365","volume":"2","author":"KA Misch","year":"1974","unstructured":"Misch KA (1974) Development of heart valve lesions during methysergide therapy. Br Med J 2(5915):365\u2013366","journal-title":"Br Med J"},{"issue":"13","key":"3441_CR10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","volume":"283","author":"JM Gardin","year":"2000","unstructured":"Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL (2000) Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine. JAMA: J Am Med Assoc 283(13):1703\u20131709","journal-title":"JAMA: J Am Med Assoc"},{"issue":"5","key":"3441_CR11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00001573-200209000-00007","volume":"17","author":"FF Seghatol","year":"2002","unstructured":"Seghatol FF, Rigolin VH (2002) Appetite suppressants and valvular heart disease. Curr Opin Cardiol 17(5):486\u2013492","journal-title":"Curr Opin Cardiol"},{"issue":"11","key":"3441_CR12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","volume":"339","author":"H Jick","year":"1998","unstructured":"Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE (1998) A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339(11):719\u2013724. doi: 10.1056\/NEJM199809103391102","journal-title":"N Engl J Med"},{"issue":"12","key":"3441_CR13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","volume":"64","author":"JC Corvol","year":"2007","unstructured":"Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L (2007) Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 64(12):1721\u20131726. doi: 10.1001\/archneur.64.12.1721","journal-title":"Arch Neurol"},{"issue":"1","key":"3441_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29\u201338. doi: 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"issue":"2","key":"3441_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","volume":"35","author":"G Trifiro","year":"2012","unstructured":"Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf 35(2):159\u2013171. doi: 10.2165\/11594940-000000000-00000","journal-title":"Drug Saf"},{"issue":"5","key":"3441_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.acvd.2009.09.015","volume":"103","author":"JP Gueffet","year":"2010","unstructured":"Gueffet JP, Piriou N, Trochu JN (2010) Valvular heart disease associated with benfluorex. Arch Cardiovasc Dis 103(5):342\u2013343. doi: 10.1016\/j.acvd.2009.09.015","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"3441_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ejechocard\/jeq172","volume":"12","author":"F Ven Le","year":"2011","unstructured":"Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Marechaux S, Eicher JC, Blanchard-Lemoine B, Rousseau J, Henon P, Jobic Y, Etienne Y (2011) Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Europ J Echocardiograp: J Working Group Echocardiography Europ Soc Cardiol 12(4):265\u2013271. doi: 10.1093\/ejechocard\/jeq172","journal-title":"Europ J Echocardiograp: J Working Group Echocardiography Europ Soc Cardiol"},{"issue":"9","key":"3441_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1191\/0961203305lu2219oa","volume":"14","author":"M Bevilacqua","year":"2005","unstructured":"Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14(9):773\u2013779","journal-title":"Lupus"},{"issue":"4 Suppl","key":"3441_CR19","first-page":"38","volume":"32","author":"CE Fiore","year":"2009","unstructured":"Fiore CE, Pennisi P, Pulvirenti I, Francucci CM (2009) Bisphosphonates and atherosclerosis. J Endocrinol Investig 32(4 Suppl):38\u201343","journal-title":"J Endocrinol Investig"},{"issue":"16","key":"3441_CR20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2012.01.024","volume":"59","author":"O Aksoy","year":"2012","unstructured":"Aksoy O, Cam A, Goel SS, Houghtaling PL, Williams S, Ruiz-Rodriguez E, Menon V, Kapadia SR, Tuzcu EM, Blackstone EH, Griffin BP (2012) Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol 59(16):1452\u20131459. doi: 10.1016\/j.jacc.2012.01.024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3441_CR21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clinthera.2010.03.014","volume":"32","author":"A John Camm","year":"2010","unstructured":"John Camm A (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 32(3):426\u2013436. doi: 10.1016\/j.clinthera.2010.03.014","journal-title":"Clin Ther"},{"issue":"4","key":"3441_CR22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/joim.12087","volume":"274","author":"EL Grove","year":"2013","unstructured":"Grove EL, Abrahamsen B, Vestergaard P (2013) Heart failure in patients treated with bisphosphonates. J Intern Med 274(4):342\u2013350. doi: 10.1111\/joim.12087","journal-title":"J Intern Med"},{"issue":"6","key":"3441_CR23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappe DL, Osborn JS, Day JD (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103(6):824\u2013828. doi: 10.1016\/j.amjcard.2008.11.037","journal-title":"Am J Cardiol"},{"issue":"1","key":"3441_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.2053","volume":"20","author":"PM Coloma","year":"2011","unstructured":"Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1\u201311. doi: 10.1002\/pds.2053","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3441_CR25","author":"PM Coloma","year":"2012","unstructured":"Coloma PM, Trifiro G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, van der Lei J, Sturkenboom M (2012) Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. doi: 10.1002\/pds.3197","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"3441_CR26","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/01.hjh.0000186832.41125.8a","volume":"23","author":"G Mazzaglia","year":"2005","unstructured":"Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23(11):2093\u20132100","journal-title":"J Hypertens"},{"issue":"4\u20135","key":"3441_CR27","first-page":"339","volume":"38","author":"AE Vlug","year":"1999","unstructured":"Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel JH (1999) Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38(4\u20135):339\u2013344. doi: 10.1267\/METH99040339","journal-title":"Methods Inf Med"},{"issue":"2","key":"3441_CR28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/pds.1245","volume":"16","author":"WG Goettsch","year":"2007","unstructured":"Goettsch WG, de Jong RB, Kramarz P, Herings RM (2007) Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf 16(2):166\u2013172. doi: 10.1002\/pds.1245","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3441_CR29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/annonc\/mdm404","volume":"19","author":"G Corrao","year":"2008","unstructured":"Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L (2008) Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 19(1):150\u2013155. doi: 10.1093\/annonc\/mdm404","journal-title":"Ann Oncol"},{"issue":"1","key":"3441_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijcard.2006.01.006","volume":"114","author":"A Barchielli","year":"2007","unstructured":"Barchielli A, Balzi D, Marchionni N, Carrabba N, Margheri M, Santoro GM, Olivotto I, Buiatti E (2007) Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry. Italy Int J Cardiol 114(1):57\u201363. doi: 10.1016\/j.ijcard.2006.01.006","journal-title":"Italy Int J Cardiol"},{"issue":"1","key":"3441_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2125.2008.03308.x","volume":"67","author":"L Smeeth","year":"2009","unstructured":"Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67(1):99\u2013109. doi: 10.1111\/j.1365-2125.2008.03308.x","journal-title":"Br J Clin Pharmacol"},{"key":"3441_CR32","unstructured":"WHO WHO DDD Classification. http:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/"},{"issue":"9689","key":"3441_CR33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","volume":"374","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374(9689):577\u2013585. doi: 10.1016\/S0140-6736(09)60252-X","journal-title":"Lancet"},{"issue":"5","key":"3441_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.acvd.2013.02.003","volume":"106","author":"M Andrejak","year":"2013","unstructured":"Andrejak M, Tribouilloy C (2013) Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 106(5):333\u2013339. doi: 10.1016\/j.acvd.2013.02.003","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"3441_CR35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/heartjnl-2012-302239","volume":"99","author":"B Cosyns","year":"2013","unstructured":"Cosyns B, Droogmans S, Rosenhek R, Lancellotti P (2013) Drug-induced valvular heart disease. Heart 99(1):7\u201312. doi: 10.1136\/heartjnl-2012-302239","journal-title":"Heart"},{"issue":"3","key":"3441_CR36","first-page":"254","volume":"8","author":"ER Mohler 3rd","year":"1999","unstructured":"Mohler ER 3rd, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH (1999) Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8(3):254\u2013260","journal-title":"J Heart Valve Dis"},{"issue":"3","key":"3441_CR37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000322902","volume":"117","author":"S Elmariah","year":"2010","unstructured":"Elmariah S, Rajamannan NM (2010) Medical therapy for calcific aortic stenosis: the use of bisphosphonates. Cardiology 117(3):229\u2013230. doi: 10.1159\/000322902","journal-title":"Cardiology"},{"issue":"1","key":"3441_CR38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1755-7682-6-24","volume":"6","author":"HP Vieira","year":"2013","unstructured":"Vieira HP, Leite IA, Araujo Sampaio TM, de Dos Anjos PJ, do Nascimento AA, de Abreu LC, Valenti VE, Goulart FC, Adami F (2013) Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med 6(1):24. doi: 10.1186\/1755-7682-6-24","journal-title":"Int Arch Med"},{"issue":"9","key":"3441_CR39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00198-013-2326-5","volume":"24","author":"K Reynolds","year":"2013","unstructured":"Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, Gold DT, Vansomphone SS, Wei R, O\u2019Malley CD (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24(9):2509\u20132517. doi: 10.1007\/s00198-013-2326-5","journal-title":"Osteoporos Int"},{"issue":"9","key":"3441_CR40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molmed.2009.07.001","volume":"15","author":"V Persy","year":"2009","unstructured":"Persy V, D\u2019Haese P (2009) Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 15(9):405\u2013416. doi: 10.1016\/j.molmed.2009.07.001","journal-title":"Trends Mol Med"},{"issue":"11","key":"3441_CR41","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jacc.2012.04.048","volume":"60","author":"MR Dweck","year":"2012","unstructured":"Dweck MR, Newby DE (2012) Osteoporosis is a major confounder in observational studies investigating bisphosphonate therapy in aortic stenosis. J Am Coll Cardiol 60(11):1027. doi: 10.1016\/j.jacc.2012.04.048 , author reply 1027","journal-title":"J Am Coll Cardiol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3441-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3441-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T07:20:30Z","timestamp":1589613630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3441-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3441"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3441-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}